Priovant Therapeutics reposted this
Priovant is excited to report finishing enrollment for the Phase 3 VALOR study of brepocitinib in dermatomyositis:
Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the heaviest patient burdens. We are rapidly developing a pipeline of medicines targeted to the specific molecular dysregulations underlying severe autoimmune conditions, unlocking new treatment options for patients who are underserved by existing therapies.
External link for Priovant Therapeutics
Durham, NC, US
Priovant Therapeutics reposted this
Priovant is excited to report finishing enrollment for the Phase 3 VALOR study of brepocitinib in dermatomyositis:
Priovant is excited to report finishing enrollment for the Phase 3 VALOR study of brepocitinib in dermatomyositis:
Excited to share our positive data for brepocitinib in non-infectious uveitis (NIU): https://lnkd.in/exqepsH3